The rationale for targeting the LOX family in cancer (original) (raw)

• Kagan, H. M. & Li, W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J. Cell Biochem. 88, 660–672 (2003).
  CAS PubMed Google Scholar
• Vadasz, Z. et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J. Hepatol. 43, 499–507 (2005).
  CAS PubMed Google Scholar
• Kim, Y. M., Kim, E. C. & Kim, Y. The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol. Biol. Rep. 38, 145–149 (2011).
  CAS PubMed Google Scholar
• Barcellos-Hoff, M. H. & Ravani, S. A. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60, 1254–1260 (2000).
  CAS PubMed Google Scholar
• Weaver, V. M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231–245 (1997). This paper shows how biomechanical environmental cues are important in controlling malignancy in three-dimensional contexts. Blocking the response of a cell to environmental stimuli through integrin inhibitors reverted the malignant phenotype of cells in vitro and in in vivo models of breast cancer.
  CAS PubMed PubMed Central Google Scholar
• Wiseman, B. S. & Werb, Z. Stromal effects on mammary gland development and breast cancer. Science 296, 1046–1049 (2002).
  CAS PubMed PubMed Central Google Scholar
• Bissell, M. J. & Radisky, D. Putting tumours in context. Nature Rev. Cancer 1, 46–54 (2001).
  CAS Google Scholar
• Erler, J. T. & Weaver, V. M. Three-dimensional context regulation of metastasis. Clin. Exp. Metastasis 26, 35–49 (2009).
  PubMed Google Scholar
• Kauppila, S., Stenback, F., Risteli, J., Jukkola, A. & Risteli, L. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J. Pathol. 186, 262–268 (1998).
  CAS PubMed Google Scholar
• Mackie, E. J. et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc. Natl Acad. Sci. USA 84, 4621–4625 (1987).
  CAS PubMed PubMed Central Google Scholar
• Zhu, G. G. et al. Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms. Cancer 75, 1010–1017 (1995).
  CAS PubMed Google Scholar
• Paszek, M. J. & Weaver, V. M. The tension mounts: mechanics meets morphogenesis and malignancy. J. Mammary Gland Biol. Neoplasia 9, 325–342 (2004).
  PubMed Google Scholar
• Paszek, M. J. et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 8, 241–254 (2005). This paper shows how matrix stiffness can perturb epithelial morphogenesis by altering the clustering of cellular integrins to enhance ERK activation and increase Rho-associated protein kinase (ROCK)-generated contractility and focal adhesions.
  CAS PubMed Google Scholar
• Bhowmick, N. A. & Moses, H. L. Tumor-stroma interactions. Curr. Opin. Genet. Dev. 15, 97–101 (2005).
  CAS PubMed PubMed Central Google Scholar
• Tlsty, T. D. & Coussens, L. M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1, 119–150 (2006).
  CAS PubMed Google Scholar
• Payne, S. L., Hendrix, M. J. & Kirschmann, D. A. Paradoxical roles for lysyl oxidases in cancer — a prospect. J. Cell Biochem. 101, 1338–1354 (2007).
  CAS PubMed Google Scholar
• Zitka, O. et al. Matrix metalloproteinases. Curr. Med. Chem. 17, 3751–3768 (2010).
  CAS PubMed Google Scholar
• Kenyon, K. et al. Lysyl oxidase and rrg messenger RNA. Science 253, 802 (1991). This is the first paper to show that the proposed RRG tumour suppressor was in fact LOX.
  CAS PubMed Google Scholar
• Contente, S., Kenyon, K., Rimoldi, D. & Friedman, R. M. Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 249, 796–798 (1990). This is the first paper to report that re-expression of RRG (later identified as LOX) in NIH 3T3 cells transformed by HRAS, leads to a reversion to normal phenotype, loss of transformation and loss of tumorigenecity in nude mice.
  CAS PubMed Google Scholar
• Giampuzzi, M. et al. Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene. J. Biol. Chem. 276, 29226–29232 (2001).
  CAS PubMed Google Scholar
• Palamakumbura, A. H. et al. The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J. Biol. Chem. 279, 40593–40600 (2004). This is the first paper to implicate the pro-peptide domain of LOX in mediating tumour suppressor functions.
  CAS PubMed Google Scholar
• Min, C. et al. The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. Cancer Res. 67, 1105–1112 (2007).
  CAS PubMed Google Scholar
• Sanchez-Morgan, N., Kirsch, K. H., Trackman, P. C. & Sonenshein, G. E. The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase-κ and inhibits β-catenin transcriptional activity in lung cancer cells. Mol. Cell. Biol. 31, 3286–3297 (2011).
  CAS PubMed PubMed Central Google Scholar
• Wu, M. et al. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Res. 67, 6278–6285 (2007).
  CAS PubMed Google Scholar
• Min, C. et al. A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer Res. 69, 6685–6693 (2009).
  CAS PubMed PubMed Central Google Scholar
• Oganesian, A. et al. The NH2-terminal propeptide of type I procollagen acts intracellularly to modulate cell function. J. Biol. Chem. 281, 38507–38518 (2006).
  CAS PubMed Google Scholar
• Wu, G. et al. LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer. Cancer Res. 67, 4123–4129 (2007).
  CAS PubMed Google Scholar
• Sun, J. et al. Hypermethylated SFRP1, but none of other nine genes “informative” for western countries, is valuable for bladder cancer detection in Mainland China. J. Cancer Res. Clin. Oncol. 135, 1717–1727 (2009).
  CAS PubMed Google Scholar
• Schmidt, H. et al. Mapping of a deletion interval on 8p21-22 in prostate cancer by gene dosage PCR. Verh. Dtsch. Ges. Pathol. 91, 302–307 (2007).
  CAS PubMed Google Scholar
• Zhan, P. et al. Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas. Med. Oncol. 29, 648–655 (2011).
  PubMed Google Scholar
• Peinado, H. et al. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res. 68, 4541–4550 (2008).
  CAS PubMed Google Scholar
• Erler, J. T. et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222–1226 (2006). This is the first paper to demonstrate a crucial role of LOX in metastasis. We showed that LOX expression is clinically correlated with hypoxia, metastasis and decreased patient survival, and demonstrated preclinical efficacy of targeting LOX against metastasis. We identified LOX as a target of HIF1 and showed LOX-mediated hypoxia-induced invasion through cell–ECM adhesion and activation of integrins and FAK.
  CAS PubMed Google Scholar
• Kirschmann, D. A. et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res. 62, 4478–4483 (2002). This is the first paper to show elevated LOX family member expression in aggressive cancer cell lines, and to show that elevated LOX expression increases cancer cell invasion in vitro.
  CAS PubMed Google Scholar
• Baker, A. M., Bird, D., Lang, G., Cox, T. R. & Erler, J. T. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene 103, 407–424 (2012).
  Google Scholar
• Baker, A. M. et al. The Role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. J. Natl. Cancer Inst. 103, 407–424 (2011). Here, we demonstrated a role for SRC in mediating LOX-driven tumour growth and metastasis in colorectal cancer in vitro, in vivo and in clinical samples. Preclinical targeting of LOX prevented both primary tumour growth and metastasis.
  CAS PubMed Google Scholar
• Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811–816 (2004).
  CAS PubMed PubMed Central Google Scholar
• Ross, D. T. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nature Genet. 24, 227–235 (2000).
  CAS PubMed Google Scholar
• Stassar, M. J. et al. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br. J. Cancer 85, 1372–1382 (2001).
  CAS PubMed PubMed Central Google Scholar
• Young, A. N. et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am. J. Pathol. 158, 1639–1651 (2001).
  CAS PubMed PubMed Central Google Scholar
• Takahashi, M. et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl Acad. Sci. USA 98, 9754–9759 (2001).
  CAS PubMed PubMed Central Google Scholar
• Decitre, M. et al. Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas. Lab. Invest. 78, 143–151 (1998).
  CAS PubMed Google Scholar
• Peyrol, S. et al. Lysyl oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma. Am. J. Pathol. 150, 497–507 (1997).
  CAS PubMed PubMed Central Google Scholar
• Barry-Hamilton, V. et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nature Med. 16, 1009–1017 (2010). This study analysed the efficacy of a LOXL2 inhibitory monoclonal antibody in reducing the pathological microenvironment associated with cancer and fibrotic disease. A reduction in activated fibroblasts, desmoplasia and endothelial cells, as well as decreased production of growth factors and cytokines and decreased TGF β signalling were observed. Decreased primary tumour growth and metastatic colonization was observed in mouse models. Importantly, safety studies demonstrate that this LOXL2 antibody could represent a new therapeutic approach in the treatment of fibrosis and aggressive cancer.
  CAS PubMed Google Scholar
• Barker, H. E. et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res. 71, 1561–1572 (2011). Our report showed clinical correlation between high LOXL2 expression and decreased overall and metastasis-free survival in patients with ER − breast cancer. We demonstrated preclinical efficacy of targeting LOXL2 genetically, chemically and immunologically in spontaneous metastatic models, abrogating lung, liver and bone metastases. We further showed that LOXL2 activity regulates the expression and activity of the matrix remodelling enzymes TIMP1 and MMP9.
  CAS PubMed Google Scholar
• Fong, S. F. et al. Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors. Genes Chromosom. Cancer 46, 644–655 (2007).
  CAS PubMed Google Scholar
• Moreno-Bueno, G. et al. Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol. Med. 3, 528–544 (2011).
  CAS PubMed PubMed Central Google Scholar
• Offenberg, H., Brunner, N., Mansilla, F., Orntoft Torben, F. & Birkenkamp-Demtroder, K. TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles. Mol. Oncol. 2, 233–240 (2008).
  PubMed PubMed Central Google Scholar
• Peng, L. et al. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 30, 1660–1669 (2009). A role for secreted LOXL2 in promoting gastric tumour invasion and metastasis via the SRC–FAK pathway was described. A LOXL2-specific antibody inhibited tumour growth and metastasis in a xenograft model.
  CAS PubMed Google Scholar
• Ruckert, F., Joensson, P., Saeger, H. D., Grutzmann, R. & Pilarsky, C. Functional analysis of LOXL2 in pancreatic carcinoma. Int. J. Colorectal Dis. 25, 303–311 (2010).
  PubMed Google Scholar
• Sano, M. et al. Forkhead box A1 transcriptional pathway in KRT7-expressing esophageal squamous cell carcinomas with extensive lymph node metastasis. Int. J. Oncol. 36, 321–330 (2010).
  CAS PubMed Google Scholar
• Grutzmann, R. et al. Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch. 443, 508–517 (2003).
  PubMed Google Scholar
• Chung, C. H. et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 66, 8210–8218 (2006).
  CAS PubMed Google Scholar
• Akiri, G. et al. Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Res. 63, 1657–1666 (2003). The first indication that LOXL2 is associated with fibrotic foci formation in breast tumours and may be a marker of poor prognosis. Increased expression of LOXL2 in non-invasive breast cancer cells gave rise to tumours with invasive properties in xenograft models.
  CAS PubMed Google Scholar
• Holtmeier, C. et al. Overexpression of a novel lysyl oxidase-like gene in human head and neck squamous cell carcinomas. Anticancer Res. 23, 2585–2591 (2003).
  CAS PubMed Google Scholar
• Weise, J. B. et al. LOXL4 is a selectively expressed candidate diagnostic antigen in head and neck cancer. Eur. J. Cancer 44, 1323–1331 (2008).
  CAS PubMed Google Scholar
• Kim, Y., Roh, S., Park, J. Y., Cho, D. H. & Kim, J. C. Differential expression of the LOX family genes in human colorectal adenocarcinomas. Oncol. Rep. 22, 799–804 (2009).
  CAS PubMed Google Scholar
• Cairns, R. A., Khokha, R. & Hill, R. P. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr. Mol. Med. 3, 659–671 (2003).
  CAS PubMed Google Scholar
• Gorogh, T. et al. Functional analysis of the 5′ flanking domain of the LOXL4 gene in head and neck squamous cell carcinoma cells. Int. J. Oncol. 33, 1091–1098 (2008).
  PubMed Google Scholar
• Sebban, S., Davidson, B. & Reich, R. Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities. Virchows Arch. 454, 71–79 (2009).
  CAS PubMed Google Scholar
• Butcher, D. T., Alliston, T. & Weaver, V. M. A tense situation: forcing tumour progression. Nature Rev. Cancer 9, 108–122 (2009).
  CAS PubMed Google Scholar
• Discher, D. E., Janmey, P. & Wang, Y. L. Tissue cells feel and respond to the stiffness of their substrate. Science 310, 1139–1143 (2005).
  CAS PubMed Google Scholar
• Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891–906 (2009). This paper reports on how the induction of collagen crosslinking by LOX stiffens the ECM, thus promoting focal adhesions, enhanced PI3K activity and inducing the invasion of an oncogene-initiated epithelium. The inhibition of integrin signalling repressed the invasion of premalignant epithelium into a stiffened, crosslinked ECM and conversely forced integrin clustering promoted focal adhesions, enhanced PI3K signalling and induced the invasion of a premalignant epithelium.
  CAS PubMed PubMed Central Google Scholar
• Yeung, T. et al. Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. Cell. Motil. Cytoskeleton 60, 24–34 (2005).
  PubMed Google Scholar
• Erler, J. T. et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15, 35–44 (2009). The first paper to report the role of LOX secreted by hypoxic breast tumour cells in the appropriation of premetastatic sites. We showed that LOX accumulates at distant sites of future metastasis and through its activity promotes the recruitment of CD11b+ bone marrow-derived cells leading to generation of growth-permissive environments that support disseminated tumour cell colonization.
  CAS PubMed PubMed Central Google Scholar
• Cox, T. R., Gartland, A. & Erler, J. T. The pre-metastatic niche: is metastasis random? BoneKEy Rep 1, 80 (2012).
  PubMed PubMed Central Google Scholar
• Fogelgren, B. et al. Cellular fibronectin binds to lysyl oxidase with high affinity and is critical for its proteolytic activation. J. Biol. Chem. 280, 24690–24697 (2005).
  CAS PubMed Google Scholar
• Boudreau, N. J. & Jones, P. L. Extracellular matrix and integrin signalling: the shape of things to come. Biochem. J. 339, 481–488 (1999).
  CAS PubMed PubMed Central Google Scholar
• Colpaert, C. et al. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 39, 416–425 (2001).
  CAS PubMed Google Scholar
• Colpaert, C., Vermeulen, P., Van Marck, E. & Dirix, L. The presence of a fibrotic focus is an independent predictor of early metastasis in lymph node-negative breast cancer patients. Am. J. Surg. Pathol. 25, 1557–1558 (2001).
  CAS PubMed Google Scholar
• Nishimura, R. et al. The fibrotic focus in advanced colorectal carcinoma: a hitherto unrecognized histological predictor for liver metastasis. Virchows Arch. 433, 517–522 (1998).
  CAS PubMed Google Scholar
• Okamoto, T. et al. Prognostic value of extracapsular invasion and fibrotic focus in single lymph node metastasis of gastric cancer. Gastr. Cancer 11, 160–167 (2008).
  CAS Google Scholar
• Sawada, S., Murakami, K., Murata, J., Tsukada, K. & Saiki, I. Accumulation of extracellular matrix in the liver induces high metastatic potential of hepatocellular carcinoma to the lung. Int. J. Oncol. 19, 65–70 (2001).
  CAS PubMed Google Scholar
• Watanabe, I. et al. Advanced pancreatic ductal cancer: fibrotic focus and β-catenin expression correlate with outcome. Pancreas 26, 326–333 (2003).
  CAS PubMed Google Scholar
• Wakasaki, H. & Ooshima, A. Immunohistochemical localization of lysyl oxidase with monoclonal antibodies. Lab. Invest. 63, 377–384 (1990).
  CAS PubMed Google Scholar
• Li, W. et al. Localization and activity of lysyl oxidase within nuclei of fibrogenic cells. Proc. Natl Acad. Sci. USA 94, 12817–12822 (1997).
  CAS PubMed PubMed Central Google Scholar
• Nellaiappan, K., Risitano, A., Liu, G., Nicklas, G. & Kagan, H. M. Fully processed lysyl oxidase catalyst translocates from the extracellular space into nuclei of aortic smooth-muscle cells. J. Cell Biochem. 79, 576–582 (2000).
  CAS PubMed Google Scholar
• Lucero, H. A. & Kagan, H. M. Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell. Mol. Life Sci. 63, 2304–2316 (2006).
  CAS PubMed Google Scholar
• Jansen, M. K. & Csiszar, K. Intracellular localization of the matrix enzyme lysyl oxidase in polarized epithelial cells. Matrix Biol. 26, 136–139 (2007).
  CAS PubMed Google Scholar
• Kagan, H. M., Williams, M. A., Calaman, S. D. & Berkowitz, E. M. Histone H1 is a substrate for lysyl oxidase and contains endogenous sodium borotritide-reducible residues. Biochem. Biophys. Res. Commun. 115, 186–192 (1983).
  CAS PubMed Google Scholar
• Giampuzzi, M., Oleggini, R. & Di Donato, A. Demonstration of in vitro interaction between tumor suppressor lysyl oxidase and histones H1 and H2: definition of the regions involved. Biochim. Biophys. Acta 1647, 245–251 (2003).
  CAS PubMed Google Scholar
• Li, W. et al. Lysyl oxidase oxidizes basic fibroblast growth factor and inactivates its mitogenic potential. J. Cell. Biochem. 88, 152–164 (2003).
  CAS PubMed Google Scholar
• Mello, M. L., Contente, S., Vidal, B. C., Planding, W. & Schenck, U. Modulation of ras transformation affecting chromatin supraorganization as assessed by image analysis. Exp. Cell Res. 220, 374–382 (1995).
  CAS PubMed Google Scholar
• Jeay, S., Pianetti, S., Kagan, H. M. & Sonenshein, G. E. Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-κB. Mol. Cell. Biol. 23, 2251–2263 (2003).
  CAS PubMed PubMed Central Google Scholar
• Pez, F. et al. The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res. 71, 1647–1657 (2011).
  CAS PubMed Google Scholar
• Basuroy, S., Dunagan, M., Sheth, P., Seth, A. & Rao, R. K. Hydrogen peroxide activates focal adhesion kinase and c-Src by a phosphatidylinositol 3 kinase-dependent mechanism and promotes cell migration in Caco-2 cell monolayers. Am. J. Physiol. Gastrointest Liver Physiol. 299, G186–G195 (2010).
  CAS PubMed PubMed Central Google Scholar
• Payne, S. L. et al. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res. 65, 11429–11436 (2005).
  CAS PubMed Google Scholar
• Csiszar, K. Lysyl oxidases: a novel multifunctional amine oxidase family. Prog. Nucleic Acid. Res. Mol. Biol. 70, 1–32 (2001).
  CAS PubMed Google Scholar
• Molnar, J. et al. Structural and functional diversity of lysyl oxidase and the LOX-like proteins. Biochim. Biophys. Acta 1647, 220–224 (2003).
  CAS PubMed Google Scholar
• Peinado, H. et al. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J. 24, 3446–3458 (2005). The first report to describe intracellular roles for LOXL2 and LOXL3 in tumour progression. LOXL2 and LOXL3 were shown to interact with and stabilize SNAI1, leading to an induction of EMT. Knockdown of LOXL2 expression in SNAI1-expressing metastatic carcinoma cells resulted in decreased tumour growth and a reduction of invasive and angiogenic markers in the resulting tumours.
  CAS PubMed PubMed Central Google Scholar
• Peinado, H., Portillo, F. & Cano, A. Switching on-off Snail: LOXL2 versus GSK3β. Cell Cycle 4, 1749–1752 (2005).
  CAS PubMed Google Scholar
• Hugo, H. et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J. Cell. Physiol. 213, 374–383 (2007).
  CAS PubMed Google Scholar
• Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Rev. Cancer 9, 265–273 (2009).
  CAS Google Scholar
• Thompson, E. W., Newgreen, D. F. & Tarin, D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 65, 5991–5995 (2005).
  CAS PubMed Google Scholar
• Higgins, D. F. et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 117, 3810–3820 (2007).
  CAS PubMed PubMed Central Google Scholar
• Schietke, R. et al. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J. Biol. Chem. 285, 6658–6669 (2010).
  CAS PubMed Google Scholar
• Postovit, L. M. et al. Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration. J. Cell. Biochem. 103, 1369–1378 (2008).
  CAS PubMed Google Scholar
• Brekhman, V. & Neufeld, G. A novel asymmetric 3D in-vitro assay for the study of tumor cell invasion. BMC Cancer 9, 415 (2009).
  PubMed PubMed Central Google Scholar
• Sethi, A., Mao, W., Wordinger, R. J. & Clark, A. F. Transforming growth factor-β induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 52, 5240–5250 (2011).
  CAS PubMed PubMed Central Google Scholar
• Voloshenyuk, T. G., Hart, A. D., Khoutorova, E. & Gardner, J. D. TNF-α increases cardiac fibroblast lysyl oxidase expression through TGF-β and PI3Kinase signaling pathways. Biochem. Biophys. Res. Commun. 413, 370–375 (2011).
  CAS PubMed Google Scholar
• Voloshenyuk, T. G., Landesman, E. S., Khoutorova, E., Hart, A. D. & Gardner, J. D. Induction of cardiac fibroblast lysyl oxidase by TGF-β1 requires PI3K/Akt, Smad3, and MAPK signaling. Cytokine 55, 90–97 (2011).
  CAS PubMed Google Scholar
• Atsawasuwan, P. et al. Lysyl oxidase binds transforming growth factor-β and regulates its signaling via amine oxidase activity. J. Biol. Chem. 283, 34229–34240 (2008).
  CAS PubMed PubMed Central Google Scholar
• Kim, D. J. et al. Lysyl oxidase like 4, a novel target gene of TGF-β1 signaling, can negatively regulate TGF-β1-induced cell motility in PLC/PRF/5 hepatoma cells. Biochem. Biophys. Res. Commun. 373, 521–527 (2008).
  CAS PubMed Google Scholar
• Hong, H. H., Uzel, M. I., Duan, C., Sheff, M. C. & Trackman, P. C. Regulation of lysyl oxidase, collagen, and connective tissue growth factor by TGF-β1 and detection in human gingiva. Lab. Invest. 79, 1655–1667 (1999).
  CAS PubMed Google Scholar
• Gacheru, S. N. et al. Transcriptional and post-transcriptional control of lysyl oxidase expression in vascular smooth muscle cells: effects of TGF-β1 and serum deprivation. J. Cell. Biochem. 65, 395–407 (1997).
  CAS PubMed Google Scholar
• Shanley, C. J. et al. Transforming growth factor-β 1 increases lysyl oxidase enzyme activity and mRNA in rat aortic smooth muscle cells. J. Vasc. Surg. 25, 446–452 (1997).
  CAS PubMed Google Scholar
• Roy, R. et al. Regulation of lysyl oxidase and cyclooxygenase expression in human lung fibroblasts: interactions among TGF-β, IL-1β, and prostaglandin E. J. Cell. Biochem. 62, 411–417 (1996).
  CAS PubMed Google Scholar
• Feres-Filho, E. J., Choi, Y. J., Han, X., Takala, T. E. & Trackman, P. C. Pre- and post-translational regulation of lysyl oxidase by transforming growth factor-β1 in osteoblastic MC3T3-E1 cells. J. Biol. Chem. 270, 30797–30803 (1995).
  CAS PubMed Google Scholar
• Blobe, G. C., Schiemann, W. P. & Lodish, H. F. Role of transforming growth factor-β in human disease. N. Engl. J. Med. 342, 1350–1358 (2000).
  CAS PubMed Google Scholar
• Taylor, M. A., Amin, J. D., Kirschmann, D. A. & Schiemann, W. P. Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells. Neoplasia 13, 406–418 (2011).
  CAS PubMed PubMed Central Google Scholar
• Palamakumbura, A. H. et al. Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene 28, 3390–3400 (2009).
  CAS PubMed PubMed Central Google Scholar
• Bais, M. V. et al. Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenografts. PLoS ONE 7, e31188 (2012).
  CAS PubMed PubMed Central Google Scholar
• Rinker-Schaeffer, C. W., O'Keefe, J. P., Welch, D. R. & Theodorescu, D. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin. Cancer Res. 12, 3882–3889 (2006).
  CAS PubMed PubMed Central Google Scholar
• Steeg, P. S. Tumor metastasis: mechanistic insights and clinical challenges. Nature Med. 12, 895–904 (2006).
  CAS PubMed Google Scholar
• Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. Nature Rev. Cancer 9, 274–284 (2009).
  CAS Google Scholar
• Gupta, G. P. & Massague, J. Cancer metastasis: building a framework. Cell 127, 679–695 (2006).
  CAS PubMed Google Scholar
• Kim, M. S. et al. Expression and purification of enzymatically active forms of the human lysyl oxidase-like protein 4. J. Biol. Chem. 278, 52071–52074 (2003).
  CAS PubMed Google Scholar
• Martin, J. E. et al. Purkinje cell toxicity of beta-aminopropionitrile in the rat. Virchows Arch. A Pathol. Anat. Histopathol 419, 403–408 (1991).
  CAS PubMed Google Scholar
• Kumar, D., Hysmith, R. M. & Boor, P. J. Allylamine and β-aminopropionitrile-induced vascular injury: an in vivo and in vitro study. Toxicol. Appl. Pharmacol. 103, 288–302 (1990).
  CAS PubMed Google Scholar
• van Boxtel, A. L., Kamstra, J. H., Fluitsma, D. M. & Legler, J. Dithiocarbamates are teratogenic to developing zebrafish through inhibition of lysyl oxidase activity. Toxicol. Appl. Pharmacol. 244, 156–161 (2010).
  CAS PubMed Google Scholar
• Gansner, J. M., Mendelsohn, B. A., Hultman, K. A., Johnson, S. L. & Gitlin, J. D. Essential role of lysyl oxidases in notochord development. Dev. Biol. 307, 202–213 (2007).
  CAS PubMed PubMed Central Google Scholar
• Halperin, E. C., Thier, S. O. & Rosenberg, L. E. The use of D-penicillamine in cystinuria: efficacy and untoward reactions. Yale J. Biol. Med. 54, 439–446 (1981).
  CAS PubMed PubMed Central Google Scholar
• Kean, W. F., Dwosh, I. L., Anastassiades, T. P., Ford, P. M. & Kelly, H. G. The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. Arthritis Rheum. 23, 158–164 (1980).
  CAS PubMed Google Scholar
• Stein, H. B., Chalmers, A., Schroeder, M. L. & Dillon, A. Selected adverse reactions of D-penicillamine. Clin. Invest. Med. 7, 73–76 (1984).
  CAS PubMed Google Scholar
• Jourdan-Le Saux, C. et al. The LOXL2 gene encodes a new lysyl oxidase-like protein and is expressed at high levels in reproductive tissues. J. Biol. Chem. 274, 12939–12944 (1999).
  CAS PubMed Google Scholar
• Barker, H. E. & Erler, J. T. The potential for LOXL2 as a target for future cancer treatment. Future Oncol. 7, 707–710 (2011).
  CAS PubMed Google Scholar
• Goodman, V. L., Brewer, G. J. & Merajver, S. D. Control of copper status for cancer therapy. Curr. Cancer Drug Targets 5, 543–549 (2005).
  CAS PubMed Google Scholar
• Pan, Q. et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 62, 4854–4859 (2002).
  CAS PubMed Google Scholar
• Smith-Mungo, L. I. & Kagan, H. M. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol. 16, 387–398 (1998).
  CAS PubMed Google Scholar
• Bennewith, K. L. & Dedhar, S. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 11, 504 (2011).
  CAS PubMed PubMed Central Google Scholar
• Wong, C. C. et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc. Natl Acad. Sci. USA 108, 16369–16374 (2011).
  CAS PubMed PubMed Central Google Scholar
• Gorogh, T. et al. Selective upregulation and amplification of the lysyl oxidase like-4 (LOXL4) gene in head and neck squamous cell carcinoma. J. Pathol. 212, 74–82 (2007).
  CAS PubMed Google Scholar
• Weise, J. B. et al. Vaccination strategy to target lysyl oxidase-like 4 in dendritic cell based immunotherapy for head and neck cancer. Int. J. Oncol. 32, 317–322 (2008).
  CAS PubMed Google Scholar
• Uzel, M. I. et al. Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. J. Biol. Chem. 276, 22537–22543 (2001).
  CAS PubMed Google Scholar
• Siegel, R. C. Collagen cross-linking. Effect of D-penicillamine on cross-linking in vitro. J. Biol. Chem. 252, 254–259 (1977).
  CAS PubMed Google Scholar
• Trackman, P. C., Bedell-Hogan, D., Tang, J. & Kagan, H. M. Post-translational glycosylation and proteolytic processing of a lysyl oxidase precursor. J. Biol. Chem. 267, 8666–8671 (1992).
  CAS PubMed Google Scholar
• Thomassin, L. et al. The Pro-regions of lysyl oxidase and lysyl oxidase-like 1 are required for deposition onto elastic fibers. J. Biol. Chem. 280, 42848–42855 (2005).
  CAS PubMed Google Scholar
• Kim, Y., Boyd, C. D. & Csiszar, K. A new gene with sequence and structural similarity to the gene encoding human lysyl oxidase. J. Biol. Chem. 270, 7176–7182 (1995).
  CAS PubMed Google Scholar
• Behmoaras, J. et al. Differential expression of lysyl oxidases LOXL1 and LOX during growth and aging suggests specific roles in elastin and collagen fiber remodeling in rat aorta. Rejuven. Res. 11, 883–889 (2008).
  CAS Google Scholar
• Hornstra, I. K. et al. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J. Biol. Chem. 278, 14387–14393 (2003).
  CAS PubMed Google Scholar
• Maki, J. M. et al. Lysyl oxidase is essential for normal development and function of the respiratory system and for the integrity of elastic and collagen fibers in various tissues. Am. J. Pathol. 167, 927–936 (2005).
  CAS PubMed PubMed Central Google Scholar
• Pischon, N. et al. Lysyl oxidase (lox) gene deficiency affects osteoblastic phenotype. Calcif. Tissue Int. 85, 119–126 (2009).
  CAS PubMed PubMed Central Google Scholar
• Lee, U. J. et al. Lower urogenital tract anatomical and functional phenotype in lysyl oxidase like-1 knockout mice resembles female pelvic floor dysfunction in humans. Am. J. Physiol. Renal Physiol. 295, F545–F555 (2008).
  CAS PubMed Google Scholar
• Jourdan-Le Saux, C., Tomsche, A., Ujfalusi, A., Jia, L. & Csiszar, K. Central nervous system, uterus, heart, and leukocyte expression of the LOXL3 gene, encoding a novel lysyl oxidase-like protein. Genomics 74, 211–218 (2001).
  CAS PubMed Google Scholar
• Asuncion, L. et al. A novel human lysyl oxidase-like gene (LOXL4) on chromosome 10q24 has an altered scavenger receptor cysteine rich domain. Matrix Biol. 20, 487–491 (2001).
  CAS PubMed Google Scholar
• Maki, J. M., Tikkanen, H. & Kivirikko, K. I. Cloning and characterization of a fifth human lysyl oxidase isoenzyme: the third member of the lysyl oxidase-related subfamily with four scavenger receptor cysteine-rich domains. Matrix Biol. 20, 493–496 (2001).
  CAS PubMed Google Scholar
• Lee, J. E. & Kim, Y. A tissue-specific variant of the human lysyl oxidase-like protein 3 (LOXL3) functions as an amine oxidase with substrate specificity. J. Biol. Chem. 281, 37282–37290 (2006).
  CAS PubMed Google Scholar
• Khakoo, A. et al. Congenital cutis laxa and lysyl oxidase deficiency. Clin. Genet. 51, 109–114 (1997).
  CAS PubMed Google Scholar
• Byers, P. H. et al. X-linked cutis laxa: defective cross-link formation in collagen due to decreased lysyl oxidase activity. N. Engl. J. Med. 303, 61–65 (1980).
  CAS PubMed Google Scholar
• Royce, P. M., Camakaris, J. & Danks, D. M. Reduced lysyl oxidase activity in skin fibroblasts from patients with Menkes' syndrome. Biochem. J. 192, 579–586 (1980).
  CAS PubMed PubMed Central Google Scholar
• Sibon, I., Sommer, P., Lamaziere, J. M. & Bonnet, J. Lysyl oxidase deficiency: a new cause of human arterial dissection. Heart 91, e33 (2005).
  CAS PubMed PubMed Central Google Scholar
• Kagan, H. M., Raghavan, J. & Hollander, W. Changes in aortic lysyl oxidase activity in diet-induced atherosclerosis in the rabbit. Arteriosclerosis 1, 287–291 (1981).
  CAS PubMed Google Scholar
• Chanoki, M. et al. Increased expression of lysyl oxidase in skin with scleroderma. Br. J. Dermatol. 133, 710–715 (1995).
  CAS PubMed Google Scholar
• Kagan, H. M. Lysyl oxidase: mechanism, regulation and relationship to liver fibrosis. Pathol. Res. Pract. 190, 910–919 (1994).
  CAS PubMed Google Scholar
• Gilad, G. M., Kagan, H. M. & Gilad, V. H. Evidence for increased lysyl oxidase, the extracellular matrix-forming enzyme, in Alzheimer's disease brain. Neurosci. Lett. 376, 210–214 (2005).
  CAS PubMed Google Scholar
• Pascual, G. et al. Down-regulation of lysyl oxydase-like in aging and venous insufficiency. Histol. Histopathol. 23, 179–186 (2008).
  CAS PubMed Google Scholar
• Zenkel, M. et al. Regulation of lysyl oxidase-like 1 (LOXL1) and elastin-related genes by pathogenic factors associated with pseudoexfoliation syndrome. Invest. Ophthalmol. Vis. Sci. 52, 8488–8495 (2011).
  CAS PubMed Google Scholar
• Schlotzer-Schrehardt, U. et al. Genotype-correlated expression of lysyl oxidase-like 1 in ocular tissues of patients with pseudoexfoliation syndrome/glaucoma and normal patients. Am. J. Pathol. 173, 1724–1735 (2008).
  PubMed PubMed Central Google Scholar
• Williams, S. E. et al. Major LOXL1 risk allele is reversed in exfoliation glaucoma in a black South African population. Mol. Vis. 16, 705–712 (2010).
  CAS PubMed PubMed Central Google Scholar
• Mori, K. et al. LOXL1 genetic polymorphisms are associated with exfoliation glaucoma in the Japanese population. Mol. Vis. 14, 1037–1040 (2008).
  CAS PubMed PubMed Central Google Scholar
• Chen, L. et al. Evaluation of LOXL1 polymorphisms in exfoliation syndrome in a Chinese population. Mol. Vis. 15, 2349–2357 (2009).
  CAS PubMed PubMed Central Google Scholar
• Pasutto, F. et al. Association of LOXL1 common sequence variants in German and Italian patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Invest. Ophthalmol. Vis. Sci. 49, 1459–1463 (2008).
  PubMed Google Scholar
• Ramprasad, V. L. et al. Association of non-synonymous single nucleotide polymorphisms in the LOXL1 gene with pseudoexfoliation syndrome in India. Mol. Vis. 14, 318–322 (2008).
  CAS PubMed PubMed Central Google Scholar
• Yang, X. et al. Genetic association of LOXL1 gene variants and exfoliation glaucoma in a Utah cohort. Cell Cycle 7, 521–524 (2008).
  PubMed Google Scholar
• Fan, B. J. et al. DNA sequence variants in the LOXL1 gene are associated with pseudoexfoliation glaucoma in a U.S. clinic-based population with broad ethnic diversity. BMC Med. Genet. 9, 5 (2008).
  PubMed PubMed Central Google Scholar
• Hewitt, A. W. et al. Ancestral LOXL1 variants are associated with pseudoexfoliation in Caucasian Australians but with markedly lower penetrance than in Nordic people. Hum. Mol. Genet. 17, 710–716 (2008).
  CAS PubMed Google Scholar
• Hayashi, H., Gotoh, N., Ueda, Y., Nakanishi, H. & Yoshimura, N. Lysyl oxidase-like 1 polymorphisms and exfoliation syndrome in the Japanese population. Am. J. Ophthalmol. 145, 582–585 (2008).
  CAS PubMed Google Scholar
• Fingert, J. H. et al. LOXL1 mutations are associated with exfoliation syndrome in patients from the midwestern United States. Am. J. Ophthalmol. 144, 974–975 (2007).
  PubMed Google Scholar
• Thorleifsson, G. et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science 317, 1397–1400 (2007).
  CAS PubMed Google Scholar
• Alarab, M., Bortolini, M. A., Drutz, H., Lye, S. & Shynlova, O. LOX family enzymes expression in vaginal tissue of premenopausal women with severe pelvic organ prolapse. Int. Urogynecol. J. 21, 1397–1404 (2010).
  PubMed Google Scholar
• Jung, H. J. et al. Changes in expression of fibulin-5 and lysyl oxidase-like 1 associated with pelvic organ prolapse. Eur. J. Obstet. Gynecol. Reprod. Biol. 145, 117–122 (2009).
  CAS PubMed Google Scholar
• Dentillo, D. B. et al. Deregulation of LOXL1 and HTRA1 gene expression in endometriosis. Reprod. Sci. 17, 1016–1023 (2010).
  CAS PubMed Google Scholar
• Ruiz, L. A. et al. Single-nucleotide polymorphisms in the lysyl oxidase-like protein 4 and complement component 3 genes are associated with increased risk for endometriosis and endometriosis-associated infertility. Fertil. Steril. 96, 512–515 (2011).
  CAS PubMed PubMed Central Google Scholar
• Akagawa, H. et al. Systematic screening of lysyl oxidase-like (LOXL) family genes demonstrates that LOXL2 is a susceptibility gene to intracranial aneurysms. Hum. Genet. 121, 377–387 (2007).
  CAS PubMed Google Scholar
• Yu, Q., Vazquez, R., Zabadi, S., Watson, R. R. & Larson, D. F. T-lymphocytes mediate left ventricular fibrillar collagen cross-linking and diastolic dysfunction in mice. Matrix Biol. 29, 511–518 (2010).
  CAS PubMed PubMed Central Google Scholar
• Zibadi, S., Vazquez, R., Larson, D. F. & Watson, R. R. T lymphocyte regulation of lysyl oxidase in diet-induced cardiac fibrosis. Cardiovasc. Toxicol. 10, 190–198 (2010).
  CAS PubMed Google Scholar
• Brekhman, V. et al. Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2. FASEB J. 25, 55–65 (2011).
  CAS PubMed Google Scholar
• Macartney-Coxson, D. P. et al. Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level. BMC Cancer 8, 187 (2008).
  PubMed PubMed Central Google Scholar
• Hollosi, P., Yakushiji, J. K., Fong, K. S., Csiszar, K. & Fong, S. F. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells. Int. J. Cancer 125, 318–327 (2009).
  CAS PubMed Google Scholar
• Bouez, C. et al. The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Clin. Cancer Res. 12, 1463–1469 (2006).
  CAS PubMed Google Scholar